Bibliografia
1. Dexter M and Allen T. Multi-talented stem cells? Nature 1992, 360:709.
2. Friedestein AJ., Gorskaja JF., Kulagia NN. Fibroblast precursors in normal and irradiated mouse hemopoietic organs. Exp Hematol 1976; 4: 267-274.
3. Jiang Y., Jahagirdar BN., Reinhardt RL.,et al. Pluripotency of mesenchymal stem cells derived from adult marrow . Nature 2002; 418: 41-49.
4. Minguell JJ, Erices A, Conget P. Mesenchymal stem cells. Exp Biol Med 2001;226:507- 520.
5. Ambrosi G, et al. Embriologia e organogenesi in Anatomia dell’uomo. Edi. Ermes, Editor 2001: Milano.
6. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. M Dominici, K Le Blanc, I Mueller, I Slaper-Cortenbach, FC Marini, DS Krause, RJ Deans, A Keating, DJ Prockop and EM Horwitz. Cytotherapy (2006) Vol. 8, No. 4, 315-317
7. Lajtha LG. Stem cell kinetics. In Gordon AS (ed): Regulation of Hematopoiesis (vol.1).
New York NY, Appleton 1970, 111.
8. Lajtha LG. Hemapoietic stem cells. Br J Haematol 1975, 29:259.
9. McCulloch EA. Control of hematopoiesis at the cellular level. In Gordon AS (ed):Regulation of Hematopoietisis (vol.1). New York NY, Appleton 1970, 33.
10. Harrison DE, Jordan CT, Zhong RK, Astle CM. Primitive hematopoietic stem cells:direct assay of most productive populations by competitive repopulation with simplebinomial, correlation and covariance calculations. Exp Hematol 1993, 21:206.
11. Potten CS, Loeffler M. Stem cells: attributes, cycles, spirals, pitfalls and uncertainties.Lesson for and from the crypt. Development 1990, 110:1001.
12. Lemischka IR, Raulet DH, Mulligan RC, Developmental potential and dynamic behaviour of hematopoietic stem cells. Cell 1986, 45:917.
13. Adams G:B ,Scodden D.T :The hematopoietic stem cell in its place .Nature Immunol 7:333,2006
14. Sutherland RD, Keating A. The Cd34 antigen: structure, biology and potential clinical applications. J Hematother 1992, 1:115.
15. Andrews RG, Singer JW, Bernstein ID. Precursors of colony-forming cells in human can be distinguished from colony-forming cells by expression of CD33 and CD34 antigens and light scatter properties. J Exp Med 1989, 169:1721.
16. Andrews RG, Singer JW, Bernstein ID. Monoclonal antibody 12.8 recognises a 115- kd molecule present on both unipotent and multipotent hematopoietic colony forming cells and their precursors. Blood 1986, 67:842.
17. Baum CM, Weissman IL Tsukamoto AS, Bucke AM. Isolation of a candidate human hematopoietic stem cell population. Proc Natl Acad Sci USA 1992, 89:2804.
18. Huang S, Terstappen LWMM. Lymphoid and myeloid differentiation of single human CD34+, HLA-DR-, CD38- hematopoietic stem cells. Blood 1994, 83:1515.
19. Civin CI, Gore SD. Antigenic analysis of hematopoiesis: a review. J Hematother 1993,2:137.
20. Mc Coullouch EA. Stem cells in normal and leukemic hematopoiesis. (Henry Stratton 38 lecture, 1982). Blood 1983, 62 : 1.
21. Greaves MF, Brown J, Molgaard HV et al. Molecular features of CD34: a hemopoietic progenitor cell-associated molecule. Leukemia 1992, 6 : 31.
22. Frithich G,Strumpfl MM,Kurz M et al:The composition of CD34 subpopulation differs between bone marrows ,blood and cord blood .Bone Marrow transpl.17 :169,1986
23. Loken MR, Shaw WO, Dattilio K, Civin CI. Flow cytometric analysis of human bone marrow. I. Normal erythroid developement. Blood 1987, 69 : 255.
24. Lansdorp PM, Sutherland HJ, Eaves CJ. Selective expression of CD45 isoforms on functional subpopulations of CD34+ hematopoietic cells from human bone marrow. J Exp Med 1990, 172 :363.
25. Caux C, Dezutter-dambuyant C, Schmidt D, Bancherau J. GM-CSF and TNF- α cooperate in the generation of dendritic Langherhans cells. Nature 1992, 360 : 258.
26. Terstappen LWMM, Huang S, Safford M et al. Sequential generation of hematopoietic colonies derived from nonlineage-committed CD34+/CD38- progenitors cells. Blood 1991, 77 : 1218.
27. Kastan MB, Schlaffer E, Russo JE et al. Direct demonstration of elevate aldehyde dehydrogenase in human hematopoietic progenitors cells. Blood 1990, 75 : 1947.
28. De Fabritiis P, Dowding C, Bunjey J et al. Phenotipic characterization of normal andCML CD34- positive cells: only the most primitive CML progenitors include Ph- neg cells. Leuk Lymphoma 1993, 11 : 51.
29. Verfaillie C, Miller WJ, Boylan K, Mc Glave PB. Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 1992, 79 : 1003.
30. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Björkholm M. Patterns of survival in multiple myeloma: a populationbased study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol2007;25:19939.(#b1)
31. Palumbo A, Anderson K. Multiple Myeloma. N Engl J Med 2011;364(11):10461060.
(#b2)
32. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myelomapathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007;7:58598.(#b3)
33. Roodman GD. Pathogenesis of myeloma bone disease. Leukemia 2009;23: 43541.(#b4) 34. Dimopoulos M, Kyle R, Fermand JP, et al. Guidelines for standard investigative workup:
report of theInternational Myeloma Workshop Consensus Panel 3. Blood. 2011 Mar 29.
(Epub ahead of print)(#b6)
35. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009; 23(1):39(#b7)
36. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serumfree light chain analysis in multiple myeloma and related disorders.
Leukemia. 2009;23(2):215224(#b8)
37. AvetLoiseauH. Role of genetics in prognostication in myeloma. Best Pract Res Clin Haematol.2007;20(4):625635.(#b9)
38. Terpos E, Moulopoulos LA, Dimopoulos MA: Advances in Imaging and the Management of Myeloma Bone Disease. J Clin Oncol. 2011;29(14):190715(b10)
39. Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, Tacchetti P, Buttignol S, Perrone G,Brioli A, Pantani L, Terragna C, Carobolante F, Baccarani M, Fanin R, Fanti S, Cavo M. Greipp PR, San Miguel J, Durie BG, et al. International staging system for
multiple myeloma. J ClinOncol 2005;23:341220.(#b13)
40. Cavo M, Rajkumar SV, Palumbo A. International Myeloma Working Group (IMWG) consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stemcell transplantation. Blood 2011 Mar 29. [Epub ahead of print] (#b14) 41. Luminari S, Cesaretti M, Rashid I et al. Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy.
Hematol Oncol 2007; 25: 189-197.
42. Morton LM, Wang SS, Devesa SS et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107: 265-276.
43. Carbone A, Ferlito A, Devaney KO, Rinaldo A. Ultrasound-guided core-needle biopsy:
is it effective in the diagnosis of suspected lymphomas presenting in the head and neck? J Surg Oncol 2008; 98: 4-5.
44. Paulli M, Artusi T, Baroni CD et al. [The Haemolymphopathology Italian Group (H.I.G.): an essential resource for the new technical and organization problems troubling modern haemolymphopathology diagnostics]. Pathologica 2006; 98: 37-40.
45. Pileri ASE. Linee guida GIE : Trattamento del campione bioptico. In Edition.
46. Jaffe ES, Banks PM, Nathwani B et al. Recommendations for the reporting of lymphoid neoplasms: a report from the Association of Directors of Anatomic and Surgical Pathology.
Mod Pathol 2004; 17: 131-135.
47. Swerdlow SHC, E.; Harris, N.L.; Jaffe, E.S.; Pileri, S.A.; Stein, H.; Thiele, J.; Vardiman, J.W. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. In Edition 4th. Lyon: IARC Press 2008.
48. Carbone A, Cesarman E, Spina M et al. HIV-associated lymphomas and gamma- herpesviruses. Blood 2009; 113: 1213-1224.
49. Garcia CF, Swerdlow SH. Best practices in contemporary diagnostic
immunohistochemistry: panel approach to hematolymphoid proliferations. Arch Pathol Lab Med 2009; 133: 756-765.
50. Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630-1636.
51. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non- Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
52. Coiffier B, Thieblemont C, Van Den Neste E et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010; 116: 2040-2045.
53. Habermann TM, Weller EA, Morrison VA et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121-3127.
54. Sehn LH, Donaldson J, Chhanabhai M et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027-5033.
55 .Pfreundschuh M, Kuhnt E, Trumper L et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011; 12: 1013-1022.
56. Brunello L, Omedè P, Bringhen S, Aglietta M, Levis A, Mordini N, Gallamini A, Fanin R, Massaia M,Palumbo A, Ciccone G, Storb R, Gooley TA, Boccadoro M, Bruno B. Long term follow up of a comparison af nonmyeloablative allografting with autografting for
newly diagnosed myeloma. Blood.2011 Jun 16;117(24):67217.(#b17)
57. Montalbán C, Piris MA. Outcome in Hodgkin’s lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005; 11:
14672473.
58.Jona A, Szodoray P, Illés A. Immunological pathomechanism of Hodgkin’s lymphoma.
Exp Hematol 2013; 41: 9951004.
59. Küppers R. The biology of Hodgkin’s lymphoma. Nat Rev Cancer 2009; 9: 1527.
60.Küpp ers R. New insight in the biology of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2012; 2012:328334.
61.Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, MullerHermelinkHK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, ChanWC, Gascoyne RD. Tumorassociated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med 2010; 362: 875885.
62. Swartz MA, Iida N, Roberts EW, Sangaletti S, Wong MH, Yull FE, Coussens LM, DeClerck YA. Tumor microenviroment complexity: emerging roles in cancer therapy.
Cancer Res 2012;72: 24732480.
63 -Az. Osp. – Univ. Pisana Programma Congiunto Trapianto CSE e Terapia Cellulare- INFORMATIVA PER IL DONATORE FAMILIARE ALLOGENICO DI CELLULE STAMINALI EMATOPOIETICHE PERIFERICHE-DV.PTUC.001 del 30/03/13
64. -Az. Osp. – Univ. Pisana Programma Congiunto Trapianto CSE e Terapia Cellulare- CONSENSO AL PERCORSO DI DONAZIONE AUTOLOGA DELLE CELLULE STAMINALI EMATOPOIETICHE PERIFERICHE (paziente maggiorenne) ,T.PTUC.018,del 30/03/13
65. -Az. Osp. – Univ. Pisana Programma Congiunto Trapianto CSE e Terapia Cellulare CONSENSO AL PERCORSO DI DONAZIONE AUTOLOGA DELLE CELLULE STAMINALI EMATOPOIETICHE PERIFERICHE (paziente minorenne),T.PTUC.019 del 30/03/13
66. -Az. Osp. – Univ. Pisana Programma Congiunto Trapianto CSE e Terapia Cellulare PROTOCOLLO OPERATIVO Valutazione idoneità alla donazione autologa di Cellule Staminali Ematopoietiche Periferiche (HPC-A)-PO.PTUC.004
67. -Az. Osp. – Univ. Pisana Programma Congiunto Trapianto CSE e Terapia Cellulare PROTOCOLLO OPERATIVO Valutazione idoneità a Trapianto di Cellule Staminali Ematopoietiche (HPC),PO.PTUC.00
68. Walker F, Roethke SK, Martin G. An overview of the rationale, process, and nursing implications of peripheral blood stem cell transplantation. Cancer Nurs. 1994;17(2):141- 148.
69. Kapustay PM. Blood cell transplantation: concepts and concerns. Semin Oncol Nurs.
1997;13(3):151-163.
70. Hooper PJ, Santas EJ. Peripheral blood stem cell transplantation. Oncol Nurs Forum.
1993;20(8):1215-1221.
71. Bakken AM. Cryopreserving human peripheral blood progenitor cells. Curr Stem Cell Res Ther. 2006;1(1):47-54.
72Fu S, Liesveld J. Mobilization of hematopoietic stem cells. Blood Rev. 2000;14(4):205- 218.
73. Nervi B, Link DC, DiPersio JF. Cytokines and hematopoietic stem cell mobilization. J
Cell Biochem. 2006;99(3):690-705.
74.Shea TC, DiPersio JF. Mobilization of autologous peripheral blood hematopoietic cells for cellular therapy. In: Applebaum FR, Forman SJ, Negrin RS, Blume KG, eds. Thomas’
Hematopoietic Cell Transplantation. Hoboken, NJ: Wiley-Blackwell;2009:590-604.
75. Bensinger W, DiPersio JF, McCarty JM. Improving stem cell mobilization strategies:
future directions. Bone Marrow Transplant.2009;43(3):181-195.
76. Perez-Simon JA, Martin A, Caballero D, Corral M, Nieto MJ, Gonzalez M, et al.
Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant.1999:24(12):1279- 1283.
77. Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant. 2008;14(9):1045-1056.
78.Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bessinger W, Comenzo RL, et al.
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD3100). Leukemia. 2009; June 25, Epub ahead of print.
79.Jansen J, Thompson JM, Dugan MJ, Nolan P, Wiemann MC, Birhiray R, et al. Peripheral blood progenitor cell transplantation.Ther Apher. 2002;6(1):5-14.
80.. Switzer GE, Goycoolea JM, Dew MA, Graeff EC, Hegland J. Donating stimulated peripheral blood stem cells vs. bonemarrow: do donors experience the procedures differently? Bone Marrow Transplant. 2001;27(9):917-923.
81. NeupogenR (filgrastim) [summary of product characteristics]. Cambridge, United Kingdom:Amgen Ltd; 2009. Please refer to the applicable national summary of product characteristics.
82. Kroger N, Renges H, Kruger W, Gutensohn K, Loliger C, Carrero I, et al. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation.
Br J Haematol. 2000;111(3):761-765.
83. CytoxanR (cyclophosphamide injection) [ prescribing information ]. Princeton, NJ:
Bristol-Myers Squibb Company; 2005.
84. MozobilR (plerixafor) [summary of product characteristics]. Naarden, The Netherlands:
Genzyme Europe B.V.;2009. Please refer to the applicable national summary of product characteristics.
85. NeupogenR (filgrastim) [ package insert ]. Thousand Oaks, CA: Amgen, Inc.; 2007.
86. Stiff PJ. Management strategies for the hard to mobilize patient. Bone Marrow Transplant. 1999;23(suppl2):S29-33.
87.Fruehauf S, Schmitt K, Veldwijk MR, et al. Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients. Br J Haematol. 1999;105(3):786-794.
88.Hicks ML, Lonial S, Langston A, et al. Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. Transfusion. 2007;47(4):629- 635
89.. Dipersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720-5726.
90.Buchsel PC, Leum E, Randolph SR. Nursing care of the blood cell transplant recipient.
Semin Oncol Nurs. 1997;13(3):172-183.
91. Reddy RL. Mobilization and collection of peripheral blood progenitor cells for transplantation. Transfus Apher Sci. 2005;32(1):63-72.
92. Perez-Simon JA, Caballero MD, Corral M, Nieto MJ, Orfao A, Vazquez L, et al.
Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation.
Transfusion.1998;38(4):385-391.
93. Basquiera AL, Abichain P, Damonte JC, Ricchi B, Sturich AG, Palazzo ED, et al. The number of CD34(+) cells in perpipheral blood as a predictor of the CD34(+) yield in patients going to autologous stem cell transplantation. J Clin Apher. 2006;21(2):92-95.
94. Cassens U, Barth IM, Naumann C, Fischer RJ, Kienast J, Vormoor J, et al. Factors affecting the efficacy of peripheral blood progenitor cells collections by large-volume leukaphereses with standardized processing volumes. Transfusion.2004;44(11):1593-1602.
95. Arslan O, Moog R. Mobilization of peripheral blood stem cells. Transfus Apher Sci.
2007;37(2):179-185.
96. Winters JL. Complications of donor apheresis. J Clin Apher. 2006;21(2):132-141.
97. Feugier P, Bensoussan D, Girard F, Alla F, Schuhmacher A, Latger-Cannard V, et al.
Hematologic recovery after autologous PBPC transplantation: importance of the number of postthaw CD34+ cells. Transfusion. 2003;43(7):878-884.
98.Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I, The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and graft engineering. J Hematother.1996 Jun5(3):213-2.
99. Verlinden A,Van de Velde A.,Verpooten GA,Van Doorn K. Determining Factores Predictive of CD34+ Cell Collection Efficiency in an Effort to Avoid Extended and Repeated Apheresis Sessions. J Clin Apher. 2013;28:404-410.
100. Villa CH,Shore T,Van Besien K,Cushing Maddition of Plerixafor to Mpobilization regimens inAutologous Peripheral Blood Stem Cell Transplants Does Not affect the Coreelation of Preharvest Hematopoietic Precursor Cell Enumeration with First-Harves CD34+ Stem Cell Yeld. Biol Blood Marrow Transplant . 2012;18:1867-1875.
101 Accorsi P,Passeri C,Iaacone A. Amultiple regression analysis on factors influencing hematopoiietic progenitor cell collection for autologous transplantation .Transfusion and Apheresis Science .2012;47:223-227.
